Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bespak Laboratories Inc. has a focused patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action. This matter is assigned to a distinct examiner working within 1 distinct art unit. Such a concentrated profile indicates that the company's current interactions with the patent office are limited to a specific technical subject. This concentration allows for a streamlined approach to patent strategy, as the applicant only needs to navigate the specific requirements of the involved administrative unit.
The busiest examiner for this portfolio is TCHERKASSKAYA, OLGA V. This examiner is responsible for 1 busiest examiner pending office action. Because there is only a single pending action in total, this examiner is managing the entire active workload for the company. Practitioners can focus their attention on this examiner's past patterns and the specific requirements of the 1 distinct art unit involved. The lack of diversity in examiners and units means that the outcome of this specific action will significantly impact the company's current patent standing in the biotechnology field. Understanding the specific examination history and preferences of this official is crucial for successfully advancing the company's interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18599091 | COMPOSITION FOR USE IN PRESSURISED DISPENSING CONTAINER | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18599091 | COMPOSITION FOR USE IN PRESSURISED DISPENSING CONTAINER | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18599091 | COMPOSITION FOR USE IN PRESSURISED DISPENSING CONTAINER | TCHERKASSKAYA, OLGA V | 1615 | §102§103§112 | Final Rejection | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBespak Laboratories Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga V Tcherkasskaya has the most, with 1 of Bespak Laboratories Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.